Cav1.2 and Cav1.3 are the main L-type Ca2+ channel subtypes in the brain. Cav1.3 channels have recently been implicated in the pathogenesis of Parkinsonâ €™ s disease. Therefore, Cav1.3-selective blockers are developed as promising neuroprotective drugs. We studied the pharmacological properties of a pyrimidine-2,4,6-trione derivative (1-(3-chlorophenethyl)-3- cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione, Cp8) recently reported as the first highly selective Cav1.3 blocker. Here we show, in contrast to this previous study, that Cp8 reproducibly increases inward Ca2+ currents of Cav1.3 and Cav1.2 channels expressed in tsA-201 cells by slowing activation, inactivation and enhancement of tail currents. Similar effects are also observed for native Cav1.3 and Cav1.2 channels in mouse chromaffin cells, while non-L-type currents are unaffected. Evidence for a weak and non-selective inhibition of Cav1.3 and Cav1.2 currents is only observed in a minority of cells using Ba2+ as charge carrier. Therefore, our data identify pyrimidine-2,4,6-triones as Ca2+ channel activators. © 2014 Macmillan Publishers Limited. All rights reserved.
CITATION STYLE
Ortner, N. J., Bock, G., Vandael, D. H. F., Mauersberger, R., Draheim, H. J., Gust, R., … Striessnig, J. (2014). Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca 2+ channel activators. Nature Communications, 5. https://doi.org/10.1038/ncomms4897
Mendeley helps you to discover research relevant for your work.